1. Principal Investigator, "Valproate in Combination with Lithium Carbonate
for the Maintenance Treatment of Bipolar Patients at High Risk for
Recurrence," Young Investigator Award, 1992-94, National Alliance for
Research on Schizophrenia and Depression, $60,000
2. Co-Principal Investigator, "Valproate in Combination with Lithium
Carbonate for the Maintenance Treatment of Bipolar Patients at High Risk for
Recurrence," 1992-94, Abbott Laboratories, $10,000
3. Investigator, "Family Treatment of Bipolar Disorder," R01 MH48171, Ivan
Miller, Principal Investigator, 9/1/92-2/28/99, National Institute of Mental
Health, $2,196,753
4. Investigator, "A Phase II, Multicenter, Randomized, Parallel-Group, Double-
Blind, Dose-Finding Study of 3 Different Doses of Roxindole vs. Placebo in
Outpatients with Major Depression," Martin B. Keller, Principal Investigator,
6/93-7/94, EM Industries, $93,492
5. Investigator, "Double-Blind Parallel Comparison of Sertraline and
Imipramine in Outpatients with Chronic Major Depression," Martin B.
Keller, Principal Investigator, 4/1/93-3/30/97, Pfizer, $600,000
6. Investigator, "Double-blind Parallel Comparison of Sertraline and
Imipramine in Outpatients with Concurrent DSM-III-R Major Depression
and Dysthymia," Martin B. Keller, Principal Investigator, 4/1/93-3/30/97,
Pfizer, $600,000
7. Investigator, "Fluoxetine vs. Sertraline and Paroxetine in Major Depression:
Comparison of Discontinuation/Emergent Signs and Symptoms," Gabor
Keitner, Principal Investigator, 9/1/96-9/1/97, Eli Lilly, $146,973
8. Investigator, "A Multi-Center Study Comparing the Safety and Efficacy of
Nefazodone HCl to Cognitive Behavioral Therapy – Chronic Depression
(CBT-CD) and Combined Nefazodone HCl and CBT-CD for the Acute,
Continuation, and Maintenance Treatment of Chronic Forms of Depression,"
Martin B. Keller, Principal Investigator, 6/1/96-5/31/99, Bristol Myers Squibb,
$798,000
9. Investigator, "Thyroxine Treatment of the Neurocognitive Side Effects of
Lithium," Independent Investigator Award, Robert Stern, Principal
Investigator, 1997-99, National Alliance for Research on Schizophrenia and
Depression, $92,592
10. Investigator, "Multicenter, Placebo-Controlled Study of Relapse Prevention by
Long-Term Treatment with Remeron in Outpatients with Major Depressive
Episode," Martin B. Keller, Principal Investigator, 9/97-3/99, Organon,
$217,000
11. Principal Investigator, "Lithium plus Valproate for Treatment of Bipolar
Disorder," Department Research Award, 1998-99, Department of Psychiatry
and Human Behavior, Brown University, $11,583
12. Investigator, "Olanzapine versus Placebo in the Treatment of Bipolar
Disorder, Manic or Mixed," Gabor Keitner, Principal Investigator, 2/98-6/99,
Eli Lilly, $279,187
13. Investigator, "Efficacy of a Family Telephone Intervention for Stroke," R01
NS37840, Ivan Miller, Principal Investigator, 9/1/98-8/30/03, National Institute of Neurological Disorders and Stroke, $2,540,523
14. Investigator, "An Eight Week, Multicenter, Parallel-Group, Double-Blind,
Placebo-Controlled Study of St. John's Wort in Outpatients with DSM-IV
Major Depression," Martin B. Keller, Principal Investigator, 9/1/98-8/31/99, Vanderbilt University and Pfizer, $138,300
15. Investigator, "Open Trial of St. John's Wort in the Treatment of Subsyndromal Depression," Ivan Miller, Principal Investigator, 1998-1999, Lifespan, $10,000
16. Investigator, "Integrative Group Treatment for Depression," R21 MH59791 Ivan Miller, Principal Investigator, 4/99-3/02, NIMH, $298,084
17. Investigator, "An Open-Label Randomized Assessment of the Efficacy and
Tolerability Venlafaxine Extended Release in Serotonin-Selective Reuptake
Inhibitor (SSRI) Failure Patients with Major Depression," Gabor Keitner,
Principal Investigator, 6/99-6/00, Wyeth-Ayerst Laboratories, $87,000
18. Investigator, "A Double-Blind Study of Two Doses of LL-759274 versus
Paroxetine Hydrochloride and Placebo in the Treatment of Outpatients with
Major Depressive Disorder," Gabor Keitner, Principal Investigator, 6/99-6/00,
Merck & Co., $221,000
19. Investigator, "Antidepressant Treatment to Reduce HIV Risk Among Injection Drug Users," R01 MH61141, Michael Stein, Principal Investigator, 9/30/99-8/31/03, NIMH $1,169,268
20. Investigator, "The Use of Mirtazapine in Reducing SSRI-Induced Sexual Side
Effects," Gabor Keitner, Principal Investigator, 3/1/00 –current, Yale
University and Organon, $198,000
21. Investigator, "Clinical Trial of Donepezil HCl (Aricept) in Diminishing
Cognitive Impairment Associated with Electroconvulsive Therapy," Robert A. Stern, Principal Investigator, 7/1/00-6/30/02, Pfizer, $136,068
22. Investigator, "Combined Treatment for Depressed Inpatients," R01 MH58866, Ivan Miller, Principal Investigator, 2/15/00-3/1/05, NIMH, $3,289,792
23. Co-investigator, "Antidepressant Treatment to Reduce HIV Risk Among Injection Drug Users," R01 MH61141, Michael Stein, Principal Investigator, 9/28/99-9/27/03, NIMH $1,815,221
24. Co-investigator, "Antidepressant Treatment to Maintain Risk Reduction Among Injection Drug Users," R01 MH62719, Michael Stein, Principal Investigator, 9/30/00-8/31/05, NIMH $2,284,149
25. Co-Principal Investigator, "Collaborative Depression Study," 2R10
MH25478-24, Martin Keller, Principal Investigator, 7/1/98-6/30/03, National
Institute of Mental Health
26. Co-Principal Investigator, "Collaborative Depression Study (no cost extension),"
2R10 MH25478-29, Martin Keller, Principal Investigator, 7/1/03-6/30/04,
National Institute of Mental Health
27. Co-Principal Investigator, "Collaborative Depression Study," 2R10
MH25478-29A2, Martin Keller, Principal Investigator, 7/1/04-6/30/09, National
Institute of Mental Health
